Scientific Reviews
Product Guides
Blogs
Topics
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!2025-02-06
1016 Results for "
Bone
" in MedChemExpress (MCE) Product Catalog:
Products (1016)
1016 Results for "Bone" in MCE Product Catalog:
Cat. No.: HY-P706008
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: GDF15; Placental Bone Morphogenetic Protein; Growth Differentiation Factor 15; Macrophage Inhibitory Cytokine 1; MIC-1; NSAID-Activated Gene 1 Protein; NAG-1; NSAID-Regulated Gene 1 Protein; PTGFB; Placental TGF-Beta; PLAB; GDF-15; MIC1; NRG-1; PDF; NSAID
Source:
HEK293
Synonyms: Nec-7
Target:
Research Areas:
Necrostatin-7 (Nec-7) is a Necroptosis inhibitor with an EC50 of 10.6 μM. Necrostatin-7 inhibits signal transduction from RANK to NFATc1 without affecting the activation of MAPK or NF-κB. Necrostatin-7 suppresses the expression levels of Acp5, Atp6v0d2, Ctsk and Dcstamp. Necrostatin-7 reduces myocardial infarction size, ameliorates adverse left ventricular remodeling, decreases myocardial wall stress, reduces the amount and length of scar tissue, and improves left ventricular function. Necrostatin-7 exerts cardioprotective effects in a rat model of permanent coronary artery occlusion. Necrostatin-7 can be used in research related to osteolytic bone diseases and myocardial infarction .
Research Areas:
Gallocyanine (NCI8642) is a DKK/LRP interaction inhibitor and Wnt/β-catenin signaling pathway activator. Gallocyanine binds to the YWTD repeat domains of LRP5/6, competitively blocks the interaction between DKK and LRP5/6, with an IC50 of approximately 3 μM for inhibiting DKK1 binding to LRP5, an IC50 of 6.38 μM for inhibiting DKK1 binding to LRP6, and a Ki of 14 μM for inhibiting the DKK2C/LRP6-E3E4 interaction. Gallocyanine reverses the inhibitory effect of DKK1 on WNT3A signaling, with an EC50 of approximately 5 μM. Gallocyanine can be used in studies related to Alzheimer's disease, bone formation and glucose metabolism .
Cat. No.: HY-13757R
CAS No.: 54965-24-1
Synonyms: ICI 46474 (Standard); (Z)-Tamoxifen Citrate (Standard); trans-Tamoxifen Citrate (Standard)
Research Areas:
Tamoxifen (Citrate) (Standard) is the analytical standard of Tamoxifen (Citrate). This product is intended for research and analytical applications. Tamoxifen Citrate (ICI 46474) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells .Tamoxifen Citrate is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen Citrate also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively . Tamoxifen Citrate activates autophagy and induces apoptosis .Tamoxifen Citrate also can induce gene knockout of CreER(T2) transgenic mouse .
Cat. No.: HY-13757S
Purity: 98.99%
Synonyms: ICI 46474-d3 hydrochloride; (Z)-Tamoxifen-d3 hydrochloride; trans-Tamoxifen-d3 hydrochloride
Synonyms: 16:0 PEG2000 PE ammonium; 1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine-N-[methoxy(polyethylene glycol)-2000] ammonium
DPPE-PEG2000 ammonium (16:0 PEG5000 PE) is a polymer-lipid conjugate and LipoParticle stabilizer with a PEG chain of 5,000 g/mol molecular weight attached to its polar head, and it can be internalized by biological membranes. DPPE-PEG2000 ammonium enables LipoParticle to maintain colloidal stability after 20-fold dilution in PBS or cell culture medium, and prevents aggregate formation during lyophilization and rehydration. DPPE-PEG2000 ammonium helps enhance the non-cytotoxic property of LipoParticle formulations against human osteoblasts. DPPE-PEG2000 ammonium serves as a PEG lipid functional end group for synthesizing liposomes (LPs), is used in the design of conjugated polymer nanoparticles, and applies to research related to bone and joint infections .
Cat. No.: HY-18102BS
Cat. No.: HY-18252S1
Cat. No.: HY-18252S3
Synonyms: TA1790-13C5
Cat. No.: HY-B1016R
CAS No.: 15421-84-8
Synonyms: AR-12008 (Standard)
Research Areas:
Trapidil (Standard) (AR-12008 (Standard)) is the analytical standard of Trapidil (HY-B1016R). This product is intended for research and analytical applications. Trapidil (AR-12008) is an orally active vasodilator and antiplatelet agent. Trapidil antagonizes platelet-derived growth factor (PDGF), inhibits phosphodiesterase, thromboxane A2 synthesis and pro-inflammatory cytokine production. Trapidil promotes prostacyclin biosynthesis, reduces lipid peroxidation, regulates nitric oxide metabolism, and inhibits cell proliferation and migration. Trapidil exerts tissue-protective effects, regulates bone turnover, and inhibits pyroptosis via the GPX3/Nrf2 pathway. Trapidil is applicable to research related to renal ischemia-reperfusion injury, chronic stable angina, restenosis, meningioma, diabetic cardiomyopathy and peripheral nerve crush injury.
Cat. No.: HY-N0026R
CAS No.: 94492-24-7
Synonyms: 2'-AA (Standard)
Cat. No.: HY-P5377
CAS No.: 221055-89-6
Synonyms: Cathepsin K substrate
Target:
Research Areas:
Target:
Research Areas:
Oxiran-2-ylmethanol (Standard) is the analytical standard of Oxiran-2-ylmethanol (Glycidol) (HY-Y1010). This product is intended for research and analytical applications. Oxiran-2-ylmethanol is an ester product. Oxiran-2-ylmethanol induces base pair point mutations in bacterial strains and structural chromosome aberrations in cultured cells. Oxiran-2-ylmethanol forms N-(2,3-dihydroxypropyl)valine hemoglobin adducts. Oxiran-2-ylmethanol acts as an animal carcinogen but does not significantly induce micronucleated immature erythrocytes in animal bone marrow. Oxiran-2-ylmethanol enables anionic polymerization to produce linear poly(glycidol). Oxiran-2-ylmethanol can be used for cancer-related research .
Cat. No.: HY-Y1010S
CAS No.: 1246819-20-4
Synonyms: Glycidol-d5
Cat. No.: HY-L171
4,388 compounds
Hematopathy, also known as hematopoietic system diseases, are a class of diseases that hematopoietic system has abnormal changes. Common hematopathy include: aplastic anemia, myeloproliferative diseases, thalassemia, leukemia, lymphoma, myeloma and hemophilia, etc. In recent years, treatments for hematopathy have been developed. In particular, the treatment of malignant hematopathy developed from chemotherapy, radiotherapy, bone marrow development to immunotherapy, induced differentiation therapy, cell therapy, gene therapy and hematopoietic stem cell transplantation. Although these therapies have greatly improved the survival rate of patients, there are still problems such as low cure rate and easy recurrence in the treatment of hematopathy. Therefore, it is of great significance to actively search for new hematopathy therapeutic drugs.
MCE designs a unique collection of 4,388 anti-hematopathy small molecules, which is an effective tool for development and research of anti-hematopathy compounds.
Cat. No.: HY-L210
2,023 compounds
Rheumatoid Arthritis (RA) is a autoimmune disease characterized by persistent joint inflammation. The pathology of RA includes immune cell infiltration, synovial lining proliferation, pannus formation, and the destruction of joint cartilage and bone, which is highly disabling. Due to long-term chronic inflammation, RA not only severely affects the quality of life of patients but can also damage multiple organs, leading to lung diseases, cardiovascular diseases, and malignant tumors. The pathogenesis of RA is complex, involving genetic, environmental, and immune factors. With the advancement of high-throughput screening technology, screening for compounds targeting JAK, CCR, MEK, MMP targets may contribute to the development of more effective drugs against Rheumatoid Arthritis (RA).
MCE has collected 2,023 small molecule compounds with definite or potential anti-rheumatoid arthritis activity. This library is of significant value for researching the anti-RA drugs.
Cat. No.: HY-P700022AF
Purity: ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: GDF6; BMP-13; Prev. SGM1; GDF6 Protein; BMP13; CDMP2; Growth/Differentiation Factor 16; SYNS4; Growth/Differentiation Factor 6; GDF-6; Bone Morphogenetic Protein 13; GDF16; KFS1; KFSL; KFS; KFM; Growth Differentiation Factor 6; Segmentation Syndrome 1
Species:
Human
Source:
E. coli
Cat. No.: HY-13757AS2
CAS No.: 3047060-10-3
Synonyms: ICI 47699-d2; (Z)-Tamoxifen-d2; trans-Tamoxifen-d2
Cat. No.: HY-16782R
CAS No.: 945614-12-0
Synonyms: ARRY-614 (Standard)
Pexmetinib (Standard) (ARRY-614 (Standard)) is the analytical standard of Pexmetinib (HY-16782). This product is intended for research and analytical applications. Pexmetinib (ARRY-614) is an orally active dual Tie-2 and p38 MAPK inhibitor. Pexmetinib binds to Tie-2 and p38 MAPK in a "DFG-out" conformation, attenuates the phosphorylation of p38, inhibits STAT3 activation, reduces the promoter-binding activity of NFATc1, and decreases the expression of MMPs. Pexmetinib inhibits leukemia cell proliferation, abrogates TNF-α-mediated myelosuppression of healthy hematopoietic stem cells, stimulates hematopoiesis in primary myelodysplastic syndrome (MDS) samples, inhibits RANKL-induced osteoclast formation and bone resorption, and suppresses migration, invasion and induced osteolysis of breast cancer cells. Pexmetinib can be used in research related to myelodysplastic syndrome, acute myeloid leukemia and breast cancer-induced osteolysis .
-
-
Protocols
Targeted therapy! The Capetin Prize winning "Click Chemistry" can be used like this!Targeted therapy! The Nobel Prize winning "Click Chemistry" can be used like this!A suitable model is crucial in drug screening experiments. Organs can mimic the three-dimensional functional structure of internal organs, have similar spatial organization to corresponding organs, maintain some key characteristics, and reproduce some physiological functions. They are widely used for modeling and personalized drug screening physiological functions.2025-02-06
